RhumbLine Advisers
CARM

RhumbLine Advisers’s Carisma Therapeutics CARM Stock Holding History

RhumbLine Advisers’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-8,387
Closed -$12.7K – 4219
2024
Q2 		$12.7K Sell
8,387
-26,701
-76% -$39.8K ﹤0.01% 3946
2024
Q1 		$79.6K Buy
35,088
+735
+2% +$1.77K ﹤0.01% 3513
2023
Q4 		$101K Sell
34,353
-10
-0% -$30 ﹤0.01% 3445
2023
Q3 		$145K Buy
34,363
+2,797
+9% +$17.7K ﹤0.01% 3323
2023
Q2 		$277K Buy
+31,566
New +$172K ﹤0.01% 3063
2022
Q2 		– Sell
-7,480
Closed -$90K – 3114
2022
Q1 		$90K Buy
7,480
+529
+8% +$7.39K ﹤0.01% 2903
2021
Q4 		$113K Sell
6,951
-171
-2% -$3.44K ﹤0.01% 2925
2021
Q3 		$113K Buy
7,122
+695
+11% +$33.4K ﹤0.01% 2982
2021
Q2 		$594K Buy
+6,427
New +$410K ﹤0.01% 2489

Other funds holding CARM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TOTUOP
Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $297M AUM
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

RhumbLine Advisers's CARM Position: Q3 2024 in Review

RhumbLine Advisers sold out of Carisma Therapeutics (CARM) in Q3 2024, closing a stake of 8,387 shares — an estimated $12.7K sold.

RhumbLine Advisers first reported a position in CARM in Q2 2021 and held it in 9 quarters. The position peaked at $594K in Q2 2021. 37 funds tracked by Wall St. Rank hold CARM as of Q3 2024.

  • RhumbLine Advisers reported no remaining Carisma Therapeutics position as of Q3 2024 after selling out during the quarter.
  • RhumbLine Advisers sold 8,387 Carisma Therapeutics shares in Q3 2024, an estimated $12.7K.
  • RhumbLine Advisers first reported a position in Carisma Therapeutics in Q2 2021 and held it in 9 quarters.
  • RhumbLine Advisers's Carisma Therapeutics position peaked at $594K in Q2 2021.
  • 37 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.